Q-Line Biotech Ltd. (QBL) is stepping forward with its maiden book-building public issue, offering investors a chance to look at its operations in the diagnostic healthcare segment. Engaged in manufacturing, developing, and marketing a diverse range of reagents, consumables, and diagnostic equipment, the company serves hospitals, medical colleges, and diagnostic service providers. More details regarding its valuation can be found in this Q-Line Biotech IPO Details: Price Band, Issue Size, and Financial Review guide.

Issue Structure and Key Dates

The company is launching an initial public offering of 6,253,200 equity shares with a face value of Rs. 10 each, aiming to raise roughly Rs. 214.48 crores at the upper end of the price band. The price band has been fixed at Rs. 326 to Rs. 343 per share. Investors must bid for a minimum application of 800 shares, with subsequent bids in multiples of 400 shares. The subscription window opens on May 21, 2026, and closes on May 25, 2026. Shares are proposed to be listed on the NSE SME Emerge platform.

Net proceeds from the offering are earmarked for specific corporate needs: Rs. 93.50 crores will support working capital requirements, Rs. 90.00 crores will go toward repaying or prepaying certain borrowings, and the remainder will fund general corporate objectives. Additionally, the company completed a pre-IPO placement of 800,000 shares in May 2026 at Rs. 343 per share, successfully raising Rs. 27.44 crores.

Financial Performance and Valuation Overview

An examination of Q-Line Biotech’s consolidated financial numbers across recent reporting periods reveals steady top-line expansion coupled with some bottom-line fluctuations. Total income and net profit figures stood at Rs. 184.81 crores and Rs. 32.10 crores in fiscal 2023, moving to Rs. 206.45 crores and Rs. 34.44 crores in fiscal 2024, and reaching Rs. 322.58 crores and Rs. 28.13 crores in fiscal 2025. For the nine-month period ending December 31, 2025, the firm recorded a net profit of Rs. 38.69 crores on a total income of Rs. 236.50 crores.

Reviewers note that while revenue has grown, the net profit dip in fiscal 2025—influenced by an extraordinary item of Rs. 16.97 crores—and the surge in pre-IPO earnings during late fiscal 2026 warrant careful attention regarding sustainability. Furthermore, overall borrowings stood at Rs. 242.57 crores and contingent liabilities reached Rs. 61.64 crores as of December 31, 2025. Based on upper-band pricing and annualized or recent earnings, the asking price translates to varying P/E multiples, leading analysts to conclude that the issue appears fully priced.

Management and Advisors

The public issue is jointly lead-managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd., while Purva Sharegistry (India) Pvt. Ltd. acts as the registrar. Hem Finlease Pvt. Ltd. serves as the market maker and syndicate member. Historical records for the lead managers indicate they have managed numerous issues over the past three years, with a small portion closing below the issue price on their respective listing dates.

Frequently Asked Questions